Topic Hub
25 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 25 of 25 clinical reviews.
A clinician-level guide to using compounded low-dose naltrexone (LDN) after bariatric surgery, covering altered pharmacokinetics, dosing strategies, safety data, and current clinical evidence.
Read clinical reviewA physician-reviewed, evidence-based breakdown of how low-dose naltrexone (LDN) affects cognitive function, brain fog, neuroinflammation, and mental clarity, including trial data, mechanisms, dosing, and clinical context.
Read clinical reviewA physician-reviewed guide to how low-dose naltrexone (LDN) affects liver enzymes and hepatic safety, covering clinical trial data, FDA labeling, monitoring protocols, and who should avoid LDN entirely.
Read clinical reviewA clinician-level review of how low-dose naltrexone (LDN) at 1.5 to 4.5 mg nightly affects libido, arousal, orgasm, and sexual pain, covering mechanisms, trial data, and prescribing guidance.
Read clinical reviewA physician-reviewed deep dive into how low-dose naltrexone (LDN) at 1.5 to 4.5 mg nightly affects sleep stages, REM suppression, and overnight TLR4-mediated microglial activity, with primary-literature citations and clinical dosing guidance.
Read clinical reviewA physician-reviewed, evidence-based look at how low-dose naltrexone (LDN) affects bone density, osteoclast activity, and fracture risk, with primary-literature citations throughout.
Read clinical reviewA clinician-level review of the evidence on low-dose naltrexone (LDN) and cancer risk, covering proposed mechanisms, human trial data, preclinical findings, and practical prescribing considerations.
Read clinical reviewA comprehensive, physician-reviewed analysis of low-dose naltrexone (LDN) and its long-term cardiovascular effects, covering mechanistic data, clinical trials, safety signals, and prescribing guidance for telehealth clinicians.
Read clinical reviewA physician-level GRADE analysis of low-dose naltrexone (LDN) covering fibromyalgia, autoimmune disease, Crohn's disease, and MS. Includes trial data, dosing, compounding considerations, and a clinical decision framework.
Read clinical reviewA physician-reviewed guide to low-dose naltrexone (LDN) for autoimmune conditions, covering mechanisms, clinical trial data, dosing, safety, and who may benefit.
Read clinical reviewA clinician-reviewed guide to how low-dose naltrexone (LDN) affects hair growth, hair loss, skin inflammation, and dermatologic autoimmune conditions, with primary-literature citations and dosing context.
Read clinical reviewA physician-reviewed deep dive into how low-dose naltrexone (LDN) affects depression, anxiety, and mood at doses of 1.5 to 4.5 mg, with primary-literature citations, clinical trial data, and prescribing guidance.
Read clinical reviewA clinician-level review of low-dose naltrexone (LDN) microdosing protocols, including standard 1.5 to 4.5 mg nightly dosing, ultra-low-dose schedules, compounding considerations, and the primary-literature evidence base for fibromyalgia, autoimmune disease, and neuroinflammation.
Read clinical reviewHow low-dose naltrexone (LDN) may support muscle preservation through glial modulation, cytokine reduction, and IGF-1 pathway effects. MD/PharmD-level review with primary literature, dosing guidance, and a decision framework.
Read clinical reviewA physician-level guide to diagnosing and resolving LDN plateaus, covering dose titration, timing adjustments, compounding quality, drug interactions, and when to switch strategies.
Read clinical reviewHow long before surgery should you stop low-dose naltrexone? This MD/PharmD-level guide covers the evidence-based hold window, opioid-antagonism pharmacokinetics, anesthesia risks, and restart timing after your procedure.
Read clinical reviewDoes stopping low-dose naltrexone cause rebound pain, inflammation, or withdrawal? A clinician-reviewed deep dive into the pharmacology, trial data, and tapering protocols for LDN discontinuation.
Read clinical reviewA clinician-level guide to adjusting low-dose naltrexone (LDN) dosing, timing, and monitoring across seasons, covering winter immune shifts, summer heat effects, and condition-specific seasonal flare patterns.
Read clinical reviewA clinician-reviewed guide to adjusting compounded low-dose naltrexone (LDN) dosing times during air travel, crossing multiple time zones, and managing circadian disruption without losing therapeutic benefit.
Read clinical reviewA physician-reviewed deep-dive into how low-dose naltrexone (LDN) may affect metabolism, thermogenesis, and energy expenditure, with primary-literature citations and clinical dosing guidance.
Read clinical reviewA clinician-reviewed guide to how low-dose naltrexone (LDN) affects appetite, food cravings, and body weight, with primary-literature citations, dosing context, and practical guidance.
Read clinical reviewA clinical deep-dive comparing compounded low-dose naltrexone (LDN) to branded naltrexone formulations, covering pharmacology, dosing, evidence base, and how to choose the right formulation for off-label indications including fibromyalgia and autoimmune conditions.
Read clinical reviewA physician-level review of low-dose naltrexone (LDN) and the kidneys: what the pharmacology, clinical trials, and safety data say about renal protection and renal risk.
Read clinical reviewA clinician-level guide to safely restarting compounded low-dose naltrexone (LDN) after an acute illness, including when to pause, how to re-titrate, and what the evidence says about opioid receptor modulation and immune function.
Read clinical reviewA week-by-week clinical guide to low-dose naltrexone (LDN), covering dose titration, sleep changes, immune effects, and what the evidence says about fibromyalgia, autoimmune conditions, and inflammation during your first 30 days.
Read clinical review